Chimeric antigen receptors are engineered receptors that combine a new specificity with an immune cell to target cancer cells. Typically, these receptors graft the specificity of a monoclonal antibody onto a T cell. CAR-T cells are a new type of treatment that uses living cells that have been transformed.
- CAR-T Cells Targeting Double Antigens
- "Off-the-Shelf" CAR-T Cells
- Challenges of CAR-T Cells in Treating Solid Tumors
- Gene Editing of T Cells
- Combination of CAR-T Cell Therapy and Other Cellular Immunotherapies
- Safety of CAR-T Cell Thearpy
- Roles of NY-ESO-TCR T Cells in Treating Solid Tumors
- Individualized HBV-Specific TCR-T Cells Targeting HCC
- Roles of CAR- and TCR-T Cells in Treatment of Solid Tumors
- Screening of TCR-T Cells with High Affinity
- Roles of WT1-TCR T Cells in Treating Leukemia
- Universal NK Technology: From PBMC-derived iPSC
- Bi-Specific Antigens Targeting NK Cells for Tumor Treatment
- CAR-NK Technology
- HCC Treatment Using Allogeneic NK Cells
- Treatment of Mid-Term and Advanced Cancers Using Autologous NK Cells
- Safety of T Cell Donors
- Preparation of Viral Vectors
- Therapeutic Efficacy Monitoring of Cell Therapy
- Standards for Cell Storage
- Preclinical Evaluation of Cell Therapy
Top experts domestic and abroad will be invited to give excellent speeches.
The latest policies of cell therapy will be analysed to pave the way for related enterprises.
Clinical trials will be promoted to strengthen focus on safety.
Personnels from Companies on Biotechnology, Cell Therapy and Investors
Clinicians
Researchers from Universities and Institutes
Dear Mr./Ms.
You have registered successfully, the registration information and attention has been sent to the contact and the participants of the mailbox, please note that check. If not received, please contact the general meeting
